New CAOT project to support internationally educated OTs in Canada

Ottawa, Ontario, June 25, 2026 (GLOBE NEWSWIRE) — A new national effort is underway to better support internationally educated occupational therapists (IEOTs) as they build their careers in Canada. The Canadian Association of Occupational Therapy (CAOT) is proud to announce the upcoming launch of The Canadian Hub for Internationally Educated Occupational Therapists: Your First Stop to OT Practice in Canada

Cloud Discovery Market Size to Surpass $9.77 Billion by 2035 as Multi-Cloud Adoption and Shadow IT Challenges Drive Enterprise Demand | Report by SNS Insider

The U.S. Cloud Discovery Market is Expected to Grow from $0.60 Billion in 2025 to $3.06 Billion by 2035, While Europe is Projected to Expand from $0.39 Billion to $1.42 Billion, Fueled by Rising Multi-Cloud Complexity, Strong Cloud Security Investments, and Regulatory Requirements Including GDPR, NIS2, and DORA Across Enterprise Environments

The U.S. Cloud Discovery Market is Expected to Grow from $0.60 Billion in 2025 to $3.06 Billion by 2035, While Europe is Projected to Expand from $0.39 Billion to $1.42 Billion, Fueled by Rising Multi-Cloud Complexity, Strong Cloud Security Investments, and Regulatory Requirements Including GDPR, NIS2, and DORA Across Enterprise Environments

Breast Cancer Liquid Biopsy Market Size to Reach USD 3.42 Billion by 2035 | SNS Insider

The U.S. Breast Cancer Liquid Biopsy Market is projected to grow from USD 0.39 Billion in 2025 to USD 0.84 Billion by 2035, while Europe is expected to expand from USD 0.35 Billion to USD 0.78 Billion, driven by increasing companion diagnostic adoption, expanding precision oncology programs, and growing utilization of ctDNA testing.

The U.S. Breast Cancer Liquid Biopsy Market is projected to grow from USD 0.39 Billion in 2025 to USD 0.84 Billion by 2035, while Europe is expected to expand from USD 0.35 Billion to USD 0.78 Billion, driven by increasing companion diagnostic adoption, expanding precision oncology programs, and growing utilization of ctDNA testing.

AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

ALPEX ACQUISITION CORPORATION ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — Alpex Acquisition Corporation (NASDAQ: ALPXU) (“Alpex”) announced the pricing of its initial public offering (the “IPO”) of 10,000,000 units at $10.00 per unit. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under “ALPXU” beginning June 25, 2026. Each unit consists of one Class A ordinary share, one redeemable warrant, and one right to receive one-fourth of one Class A ordinary share upon consummation of an initial business combination. Each whole redeemable warrant entitles the holder thereof to purchase one Class A ordinary share at an exercise price of $11.50 per share. Upon separate trading, the Class A ordinary shares, warrants and rights are expected to be listed on Nasdaq under “ALPX,” “ALPXW,” and “ALPXR,” respectively.